Open an account

Enliven Therapeutics

ELVN · NASDAQ

$41.25+$2.55 (+6.59%)TodayMarket closed ·
Prev close $38.70

About ELVN

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. The company is headquartered in Boulder, Colorado and currently employs 60 full-time employees. The company went IPO on 2020-03-12. The company is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.

Employees
60
Headquarters
Boulder, Colorado
Listed
Mar 12, 2020
Sector
Health Care
Industry
Pharmaceuticals
Website
enliventherapeutics.com

ELVN key statistics

Market cap
3.02B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.27M
Volume
1.94M
Open price
$38.86
High today
$41.37
Low today
$38.41
52 Week high
$62.32
52 Week low
$14.79

Enliven Therapeutics (ELVN) at a glance

Enliven Therapeutics (ELVN) last traded at $41.25, with a market cap of 3.02B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $38.41 and $41.37. The current price is 7.4% above the day's low and 0.3% below its high.

Volume so far is 1.94M shares, above the average of 1.27M shares a day.

Over the past year Enliven Therapeutics has ranged from $14.79 to $62.32, and now sits 56% of the way up that range.

Enliven Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.49 per share against an estimate of -$0.4062.

The average analyst price target is $74.92, 81.6% above the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 10 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 13 analystsAvg $74.92
Low
$65.65
Now
$41.25
High
$86.10

ELVN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 15.2% on average.

  1. Q3 FY24: reported -$0.48 per share against an estimate of -$0.5068
  2. Q4 FY24: reported -$0.46 per share against an estimate of -$0.5319
  3. Q1 FY25: reported -$0.57 per share against an estimate of -$0.5147
  4. Q2 FY25: reported -$0.49 per share against an estimate of -$0.5446
  5. Q3 FY25: reported -$0.32 per share against an estimate of -$0.4424
  6. Q4 FY25: reported -$0.48 per share against an estimate of -$0.3853
  7. Q1 FY26: reported -$0.38 per share against an estimate of -$0.472
  8. Q2 FY26: reported -$0.49 per share against an estimate of -$0.4062

ELVN news

  • Press releasePRNewswire

    Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year

  • Press releasePRNewswire

    Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia

  • Press releasePRNewswire

    Enliven Therapeutics to Present at Upcoming Investor Conferences

  • Press releasePRNewswire

    Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

  • Vandana Singh

    Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says

  • Press releasePRNewswire

    Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

  • Press releasePRNewswire

    Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

  • Press releasePRNewswire

    Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

Similar companies

Companies in the same industry as Enliven Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.